臨床整形外科54巻7号

2019年07月発行

誌上シンポジウム 骨軟部腫瘍の薬物治療アップデート

軟部肉腫に対する免疫療法の開発状況

著者： 遠藤誠¹ 薛宇孝¹ 藤原稔史¹ 中川亮¹ 八尋健一郎¹ 木村敦¹ 島田英二郎¹ 廣瀬毅¹ 中島康晴¹ 松本嘉寛¹

所属機関： ¹九州大学医学部整形外科学教室

ページ範囲：P.689 - P.695

　免疫チェックポイント阻害薬がさまざまな悪性腫瘍に有効であるとの報告が相次ぎ，がん免疫療法に大きな期待が集まっている．残念ながら，免疫チェックポイント阻害薬の骨軟部腫瘍に対する効果は限定的であり，一部の組織型を除き，開発が進んでいないのが現状である．一方で，軟部肉腫に対してNY-ESO-1抗原特異的TCR遺伝子導入Tリンパ球輸注療法が有効との結果が少しずつ出始めており，大きな期待を集めている．本稿では，軟部肉腫に対する免疫療法の開発状況について，今までに得られている結果とともに，現在行われている治験の情報を含め，概説することとする．

参考文献

1) Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11(11):3887-95.

2) D'Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 2015;46(3):357-65.

3) Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 2013;8(12):e82870. doi:10.1371/journal.pone.0082870.

4) Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028):a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017;18(11):1493-1501.

5) Maki RG, Jungbluth AA, Gnjatic S, et al. A Pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013;2013:168145.

6) D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401):two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 2018;19(3):416-26.

7) Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997;94(5):1914-8.

8) Endo M, de Graaff MA, Ingram DR, et al. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 2015;28(4):587-95.

9) Hemminger JA, Ewart Toland A, Scharschmidt TJ, et al. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod Pathol 2013;26(2):282-8.

10) Iura K, Kohashi K, Hotokebuchi Y, et al. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res 2015;1(3):144-59.

11) Iura K, Maekawa A, Kohashi K, et al. Cancer-testis antigen expression in synovial sarcoma:NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol 2017;61:130-9.

12) Jungbluth AA, Antonescu CR, Busam KJ, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001;94(2):252-6.

13) Lai JP, Robbins PF, Raffeld M, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors:significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol 2012;25(6):854-8.

14) Pollack SM, Jungbluth AA, Hoch BL, et al. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 2012;118(18):4564-70.

15) Shurell E, Vergara-Lluri ME, Li Y, et al. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. Oncotarget 2016;7(45):72860-7.

16) Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314(5796):126-9.

17) Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor:long-term follow-up and correlates with response. Clin Cancer Res 2015;21(5):1019-27.

18) Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29(7):917-24.

19) JMACCT 臨床試験登録システム(https://dbcentre3.jmacct.med.or.jp/jmactr/default.aspx?JMACCTID=JMA-IIA00346)